Charles Baum, M.D., Ph.D., who oversaw Mirati Therapeutics’ $5.8 billion sale to Bristol Myers Squibb last year, is taking the helm of young biotech Terremoto Biosciences.

Edwards Lifesciences is dropping about $1.6 billion on a pair of acquisitions to bolster its structural heart portfolio.

After 15 years as head of the FDA’s Center for Devices and Radiological Health, Jeff Shuren, M.D., is retiring.

Novartis has had some bad luck with bispecific antibodies in the past, but judging by the pharma’s latest deal it still has faith in the modality.

Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.

After reaching out to more than 200 companies to partner a Tourette syndrome therapy that showed the ability to beat standard of care last year, Asarina Pharma has come up empty and will fold.

Revenue for clinical research services company IQVIA was boosted by 2.3% in the second quarter compared to the prior-year period, thanks to better-than-expected performance from the company’s technology and analytics solutions offerings.

Tulavi Therapeutics has received a de novo clearance from the FDA for a surgical kit designed to help reduce long-term phantom limb pains among people who have had an amputation.

Flagship Pioneering has thrown $50 million behind a push to create synthetic proteins that overcome the limitations of natural biologics. The money will support Abiologics, a biotech that has grown out of three years of work at Flagship to create a platform capable of birthing the new modality.

GE HealthCare will spend about $51 million in cash to acquire artificial intelligence assets from Intelligent Ultrasound Group, with tech that provides real-time support to clinicians during OB/GYN exams.